Cyclic peptides have emerged as a promising class of therapeutic agents, bridging the gap between small molecules and biologics. Their unique macrocyclic structure provides enhanced stability, high binding affinity, and the ability to target challenging protein-protein interactions. However, the discovery and optimization of cyclic peptide drugs have traditionally been hindered by low synthesis efficiency, poor oral bioavailability, and unpredictable pharmacokinetic properties. At CD ComputaBio, we address these challenges by integrating cutting-edge artificial intelligence with computational chemistry and experimental validation. Our AI-powered platform accelerates every stage of cyclic peptide drug discovery, from library design to lead optimization and wet-lab validation. Below are our core services designed to help pharmaceutical companies, biotechnology firms, and research institutions bring next-generation cyclic peptide therapeutics to market faster and more efficiently.
The foundation of successful cyclic peptide drug discovery lies in the quality and diversity of the screening library. CD ComputaBio offers AI-Accelerated Cyclic Peptide Library Design & Customization services that leverage deep generative models to create highly diverse, drug-like cyclic peptide libraries tailored to specific therapeutic targets. Our AI algorithms explore vast chemical spaces far beyond the reach of traditional combinatorial chemistry, generating millions of virtual cyclic peptide structures with optimized physicochemical properties.
Oral bioavailability remains one of the greatest challenges in cyclic peptide drug development. Most cyclic peptides are too large and polar to penetrate the intestinal epithelium, limiting their administration to parenteral routes. CD ComputaBio's AI-Driven Oral Cyclic Peptide Drug Design Service directly addresses this challenge. Our proprietary AI models predict and optimize key determinants of oral absorption, including membrane permeability, gastrointestinal stability, and efflux transporter avoidance.
Understanding the absorption, distribution, metabolism, excretion, and toxicity (ADMET) profile of a drug candidate is critical for successful development. CD ComputaBio provides a dedicated Oral Cyclic Peptide ADMET Prediction Service powered by advanced machine learning models. Our platform predicts key ADMET parameters specifically calibrated for cyclic peptide scaffolds, including human intestinal absorption, plasma protein binding, volume of distribution, cytochrome P450 metabolism susceptibility, clearance rate, half-life, and potential toxicity endpoints such as hepatotoxicity and nephrotoxicity.
Once a lead cyclic peptide candidate has been identified, systematic optimization is required to enhance its potency, selectivity, stability, and pharmacokinetic properties. CD ComputaBio's Oral Cyclic Peptide Drug Optimization Service combines generative AI with computational binding prediction and structural biology. Our platform explores chemical modifications—including amino acid substitutions, side chain modifications, backbone cyclization patterns, and stereochemical changes—that improve target binding affinity while maintaining or enhancing oral bioavailability. We perform virtual alanine scanning, free energy perturbation calculations, and molecular dynamics simulations to predict the impact of each modification.
Computational predictions, no matter how sophisticated, must ultimately be confirmed by experimental data. CD ComputaBio offers a comprehensive Oral Cyclic Peptide Wet-Lab Validation Service to bridge the gap between in silico design and biological testing. Our state-of-the-art laboratory facilities support a full range of validation assays, including solid-phase peptide synthesis (SPPS) of designed cyclic peptides, purification and characterization by HPLC and mass spectrometry, binding affinity measurements using surface plasmon resonance (SPR) or fluorescence polarization, cell-based functional assays, in vitro permeability assays (Caco-2 or PAMPA), metabolic stability assays in liver microsomes or hepatocytes, and preliminary in vivo pharmacokinetic studies.
CD ComputaBio stands at the intersection of artificial intelligence, computational chemistry, and experimental biology. Our platform is specifically optimized for cyclic peptide therapeutics, addressing the unique challenges of this drug modality. We offer end-to-end services from library design through wet-lab validation, providing seamless integration at every stage. Our team of experienced scientists combines deep expertise in AI, peptide chemistry, and drug discovery to deliver high-quality results on accelerated timelines. Whether you are initiating a new cyclic peptide discovery program or optimizing an existing lead series, CD ComputaBio is your trusted partner for AI-accelerated cyclic peptide drug development.
